Business Wire

Tempo Acquires ALM Works to Deliver Integrated Strategic Portfolio Management Offering

22.12.2021 20:17:00 EET | Business Wire | Press release

Share

Tempo Software, the leader in team time management and productivity-enhancing solutions, today announced the acquisition of ALM Works, developer of the Structure for Jira software suite that enables project and program managers to make better decisions, work more efficiently, and deliver predictable results. A top-selling project management solution, ALM Works helps over 5000 organizations worldwide visualize, track and manage progress across large-scale, complex projects. Tempo and ALM Works together will provide the first suite of purpose-built program management apps to meet project, program and portfolio management needs for over 70 million users within the Atlassian Ecosystem.

The combination of Tempo’s team time and capacity management solutions and ALM Works’ project and artifact structuring solutions will enable program managers to easily understand whether key initiatives are on track and meeting strategic objectives. A recent Tempo survey showed that 55% of software development executives reported that they use time tracking insights to inform project and portfolio management. This new combination of Tempo and ALM Works will provide organizations with the visibility required to move between strategy and daily execution, make informed decisions, and share progress with executives and stakeholders.

“For over a decade, ALM Works has set themselves apart within the Atlassian Ecosystem due to their focused efforts on helping bring structure to complex project data,” said Mark Lorion, CEO, Tempo Software. “Through an even tighter integration with ALM Works, we are excited to bring a modern, easy-to-use and scalable program management solution to market and to our many shared customers and partners. Together we will uniquely support the teams who operate within Jira on a daily basis and provide the data that senior leadership teams need to be responsive as they set product strategy for an organization.”

“ALM Works focuses on enabling project and program managers to solve complex problems with our flexible, adaptable Structure solution,” said Igor Sereda, ALM Works CEO. “By bringing ALM Works together with Tempo’s industry-leading time tracking and productivity management suite of products, we’re now well-positioned to deliver the most comprehensive program and portfolio management offering to the market. I am proud of the work our team has accomplished over the past 17 years and look forward to bringing visibility and strategic insights to even more people and teams.”

Combined with the recent acquisition of Roadmunk, the addition of ALM Works strengthens Tempo’s strategic portfolio management offering. As a modern and integrated solution suite, Tempo will meet the growing needs of today’s distributed and complex product organizations who need to project, plan, and adapt based on timely organizational capacity data and insights.

Supporting Resources:

About Tempo
Tempo Software offers integrated applications for time management, resource planning, and budget management for software engineering and product management teams. Our customers gain an unrivaled understanding of time and effort, and they improve how their teams plan and manage their work. This provides an aligned understanding of and plan for how time –the most precious, and finite resource–is optimized. Tempo Software is seamlessly integrated across popular DevOps tools and a natural and automated part of users’ workflows.

Headquartered in Boston and with offices in Reykjavik, Iceland and Montreal, Canada, Tempo Software is one of the largest and most successful companies in the Atlassian ecosystem.

Tempo has more than 20,000 customers across a range of industries in more than 100 countries. It works with hundreds of partners around the world, offering resale, training, and consultancy in local languages. Tempo is available in English, French, German, Spanish, Portuguese, and Russian, with Japanese coming soon. To learn more about Tempo, visit www.tempo.io

About ALM Works
ALM Works provides software products to empower project managers around the world with visibility and control. ALM Works’ flagship product, Structure for Jira, is a project and portfolio management tool for Atlassian, used by thousands of customers in over 100 countries. Structure, together with its extensions such as Structure.Gantt, is made for project managers and other people responsible for planning, tracking, and getting things done at an organization. It allows them to work efficiently, deliver predictable results, see problems earlier, make better decisions and communicate with clarity and confidence to their teams, managers and clients.

ALM Works is headquartered in Boston with offices in Saint-Petersburg, Russia. To learn more about ALM Works, visit almworks.com.

About Diversis Capital, L.P.
Founded in 2013, Diversis is a software and technology focused private equity fund with $1bn+ in AUM that invests in lower middle-market companies, targeting situations where it can add unique value in helping a company reach the next level. With a collaborative approach to investing, its Operating Partners and Strategic Advisors work alongside management teams to help build successful organizations positioned for long-term growth. To learn more, visit www.diversis.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Escalate PR for Tempo.io
tempo@escalatepr.com

Joel Richman
joel@escalatepr.com
+1 617 312 5942

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye